Summit Therapeutics Inc. Common Stock Earnings Dividend
Earnings Summary
Revenue | $0Mn |
Net Profits | $-215.7Mn |
Net Profit Margins | -Inf% |
Summit Therapeutics Inc. Common Stock’s revenue jumped NaN% since last year same period to $0Mn in the Q2 2026. On a quarterly growth basis, Summit Therapeutics Inc. Common Stock has generated NaN% jump in its revenue since last 3-months.
Summit Therapeutics Inc. Common Stock’s net profit jumped 6.94% since last year same period to $-215.7Mn in the Q2 2026. On a quarterly growth basis, Summit Therapeutics Inc. Common Stock has generated -13.87% fall in its net profits since last 3-months.
Summit Therapeutics Inc. Common Stock’s net profit margin jumped NaN% since last year same period to -Inf% in the Q2 2026. On a quarterly growth basis, Summit Therapeutics Inc. Common Stock has generated NaN% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | -0.22 |
EPS Estimate Current Year | -0.22 |
Summit Therapeutics Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.22 - a 15.38% jump from last quarter’s estimates.
Summit Therapeutics Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.22.
Key Ratios
Earning Per Share (EPS) | -0.28 |
Summit Therapeutics Inc. Common Stock’s earning per share (EPS) fell -133.33% since last year same period to -0.28 in the Q2 2026. This indicates that the Summit Therapeutics Inc. Common Stock has generated -133.33% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-07-23 | -0.26 | -0.28 | -7.69% |
2026-04-30 | -0.12 | -0.18 | -45.19% |
